Trial Profile
Phase I Trial of Induction Dasatinib Therapy in Patients with Resectable Malignant Pleural Mesothelioma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Malignant-mesothelioma
- Focus Biomarker; Pharmacodynamics
- 27 Oct 2022 Status changed from active, no longer recruiting to completed.
- 27 Apr 2022 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.
- 27 Apr 2022 Planned primary completion date changed from 31 Mar 2022 to 31 Mar 2023.